Science discovers a way for bones to repair themselves

Scientists may have found a new way to help the body rebuild its own bones. The key is a receptor called GPR133, a kind of surface switch that turns on bone-forming cells.

When researchers activated this switch with a compound called AP503, mice grew stronger, healthier bones – even in models of osteoporosis. The discovery hints at a new direction for future bone therapies.

How the bone switch works

Bones stay strong when two cell teams stay in balance. Osteoblasts, cells that form new bone matrix and minerals, need to match the cleanup work of osteoclasts.

The work was led by Ines Liebscher, Professor of Signal Transduction at Leipzig University. Her research focuses on adhesion G protein-coupled receptors and how cells translate forces and chemical cues.

The team pinpointed GPR133, a G protein-coupled receptor (GPCR), a membrane protein that relays outside signals into the cell, as a control lever for osteoblast activity. When this GPCR was switched on, osteoblasts matured and laid down sturdier bone.

“Using the substance AP503, which was only recently identified via a computer-assisted screen as a stimulator of GPR133, we were able to significantly increase bone strength in both healthy and osteoporotic mice,” said Liebscher.

Bone repair and GPR133

Mice bred without the GPR133 gene developed thinner, weaker bones. When researchers turned the receptor on with AP503 in normal mice, bone volume and strength rose, and bone structure looked healthier.

The receptor did not respond in knockout animals, a sign that AP503 works through GPR133 itself. That is important because it ties the drug’s action to the intended target.

Exercise added another layer. Treadmill running and AP503 together produced stronger effects than either alone in young mice. That match between movement and chemistry fits the biology of bone.

The team also tested a menopause model in which estrogen loss triggers bone loss. AP503 pulled key measures back toward normal, including osteoblast counts, while signs of bone resorption eased.

Linking force to GPR133 activity

Bones respond to load because cells can sense strain. That process, mechanotransduction – cells turning physical force into biochemical signals – helps set how much bone the body builds or removes. A recent review lays out how critical this is for repair and daily maintenance.

The GPR133 receptor appears tuned to both force and a partner molecule on neighboring cells. Inside the cell, the signal boosts cyclic AMP (cAMP), a small messenger that switches on enzymes, and which leads to downstream changes that favor bone formation.

One of those changes touches beta-catenin, a protein that helps turn on bone building genes. The canonical Wnt pathway uses beta catenin to drive osteoblast programs.

Multiple studies show how essential it is for bone maintenance. A comprehensive review details Wnt’s central role across development and repair.

This offers a clean story. Mechanical load and cell-to-cell cues feed into GPR133. The GPCR raises cAMP and stabilizes beta catenin, which nudges precursor cells toward mature bone-forming cells.

Why GPR133 matters

Osteoporosis carries a steep price. In the United States, experts project 3 million fractures in 2025, with costs around $25.3 billion, according to the Bone Health and Osteoporosis Foundation. That cost lands on families and on the health system.

Most approved drugs slow breakdown or briefly stimulate formation. Some come with rare but serious side effects, and several lose punch if used too long.

A therapy that safely restores the formation side of the balance, without blunting the cleanup crew, would shift the landscape.

This mouse work sketches that path. It also makes room for lifestyle. If a pill and regular, sensible exercise amplify each other, clinics could tailor plans that fit age, mobility, and fracture risk.

There are hurdles to clear. The study is preclinical, and mouse bones differ from human bones in structure and remodeling tempo. The drug’s safety, dose range, and off-target effects will need careful testing before any clinical trial.

“The newly demonstrated parallel strengthening of bone once again highlights the great potential this receptor holds for medical applications in an aging population,” said molecular biologist Juliane Lehmann, from the University of Leipzig.

Future of bone health

Three uncertainties will shape the road ahead. First is durability, whether receptor activation can keep formation up for months without unwanted calcification elsewhere.

Second is specificity. GPCRs are common, so drug developers will need clean selectivity for GPR133 to avoid cross-talk with other receptors that also use cAMP. Selectivity will matter for dosing and for side effect profiles.

Third is who benefits. Human genetic studies have linked GPR133 variants to bone mineral density and body height. That opens the door to testing whether patients with certain variants respond better to a GPR133 agonist.

If future trials confirm these effects in people, the clinic could gain a medicine that works with the body’s own programs. Stronger bones from the inside would reduce fractures and extend independent living.

Basic physiology supports that hope. Bones are built to sense load and adapt. A carefully tuned GPCR signal that shoulders more of that job could make age-related bone loss less inevitable.

The study is published in Signal Transduction and Targeted Therapy.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–